{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:29:23Z","timestamp":1784302163648,"version":"3.55.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cladribine tablets are an oral short-course disease-modifying therapy (DMT) approved for the treatment of highly active relapsing multiple sclerosis (MS). While their efficacy has been demonstrated in clinical trials, limited real-world evidence is available on their impact on patient-reported outcomes (PROs) and the potential added value of wearable devices for continuous functional monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the association between cladribine tablets use and PROs related to physical functioning and quality of life, and to explore the relationship between PROs and biometric data collected through wearable devices over 52\u202fweeks in a real-world cohort of patients with highly active MS after therapeutic switch.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CLADFIT-MS is a prospective, multicenter, observational phase IV study conducted in Italy. This interim analysis includes 190 patients with highly active MS who initiated cladribine tablets and had data available up to Week 52. PROs included the Multiple Sclerosis Impact Scale (MSIS-29), EuroQoL-5D-5L, and PROMIS-29 physical function and fatigue scores. Biometric data (e.g., range of movement, walking distance, sleep time) were collected using Fitbit\u00ae devices. Associations between PROs and wearable-derived data were analyzed using univariate mixed models and correlation matrices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MSIS-29 physical scores and EQ-5D-5L remained stable over 52\u202fweeks. PROMIS-29 fatigue scores showed slight improvement [from 54.6 (9.59) to 51.8 (10.30)], while PROMIS-29 physical function scores remained stable. An exploratory association was observed between baseline range of movement and changes in MSIS-29 scores (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.0425), and between walking distance and PROMIS-29 fatigue (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.0345). Biometric variables demonstrated moderate to strong inter-correlations, suggesting internal consistency of the wearable-derived data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort of patients with highly active MS, cladribine tablets treatment was associated with the maintenance of PROs over one year. The integration of wearable technology provided objective metrics that were consistent with patient perceptions, supporting the feasibility of combining digital tools with PROs to monitor functional outcomes in MS clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1765153","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:32:21Z","timestamp":1775831541000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of cladribine tablets on PROs in patients with MS: insights from the 1st interim analysis of the CLADFIT-MS study"],"prefix":"10.3389","volume":"17","author":[{"given":"Giovanna","family":"Borriello","sequence":"first","affiliation":[{"name":"Multiple Sclerosis Center, San Pietro Fatebenefratelli Hospital","place":["Rome, Italy"]},{"name":"Department of Public Health, Federico II University","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Grazia","family":"Chisari","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania","place":["Catania, Italy"]},{"name":"UOS Multiple Sclerosis, AOU Policlinico \"G Rodolico-San Marco\", University of Catania","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Maimone","sequence":"additional","affiliation":[{"name":"Centro Sclerosi Multipla, UOC Neurologia, Azienda Ospedaliera per l'Emergenza Cannizzaro","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Matta","sequence":"additional","affiliation":[{"name":"Centro Sclerosi Multipla, UOC Neurologia, Ospedale Garibaldi-Centro","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Mirabella","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center, Fondazione Policlinico Universitario \"A. Gemelli\" IRCCS","place":["Rome, Italy"]},{"name":"Centro di Ricerca per la Sclerosi Multipla \"Anna Paola Batocchi\", Dipartimento di Neuroscienze, Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Paolicelli","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Translational Biomedicine and Neuroscience (DiBraiN), Policlinico General Hospital, University of Study of Bari","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Assogna","sequence":"additional","affiliation":[{"name":"Merck Serono S.p.A., an Affiliate of Merck KGaA","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Caradonna","sequence":"additional","affiliation":[{"name":"Merck Serono S.p.A., an Affiliate of Merck KGaA","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania","place":["Catania, Italy"]},{"name":"UOS Multiple Sclerosis, AOU Policlinico \"G Rodolico-San Marco\", University of Catania","place":["Catania, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis \u2013 a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1212\/WNL.0000000000012323","article-title":"Secondary progressive multiple sclerosis: new insights","volume":"97","author":"Cree","year":"2021","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","article-title":"Treatment of multiple sclerosis - success from bench to bedside","volume":"15","author":"Tintore","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e041249","DOI":"10.1136\/bmjopen-2020-041249","article-title":"Quality of life in adults with multiple sclerosis: a systematic review","volume":"10","author":"Gil-Gonz\u00e1lez","year":"2020","journal-title":"BMJ Open"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","article-title":"Brain health: time matters in multiple sclerosis","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult Scler"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing-remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult Scler"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"101594","DOI":"10.1016\/j.msard.2019.11.069","article-title":"Long term effectiveness of cladribine in patients enrolled in the CLARITY trial: real world experience from the Lebanese cohort","volume":"37","author":"Yamout","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1756286420922685","DOI":"10.1177\/1756286420922685","article-title":"Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS)","volume":"13","author":"Patti","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10354-022-00931-4","article-title":"Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety","volume":"172","author":"Moser","year":"2022","journal-title":"Wien Med Wochenschr"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2174\/1570159X21666230322140711","article-title":"Real-world effectiveness of Cladribine for patients with multiple sclerosis: a Sicilian multicentric experience (rewind study)","volume":"22","author":"Arena","year":"2024","journal-title":"Curr Neuropharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"104951","DOI":"10.1016\/j.msard.2023.104951","article-title":"Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: the CLARENCE study","volume":"79","author":"Brownlee","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fneur.2020.00489","article-title":"Single-center 8-years clinical follow-up of cladribine-treated patients from phase 2 and 3 trials","volume":"11","author":"Moccia","year":"2020","journal-title":"Front Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1007\/s12325-023-02682-z","article-title":"Evaluation of patient-reported outcomes in patients with relapsing multiple sclerosis treated with Cladribine tablets in the CLAWIR study: 12-month interim analysis","volume":"40","author":"Rau","year":"2023","journal-title":"Adv Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40263-017-0412-5","article-title":"Outcome measures in clinical trials for multiple sclerosis","volume":"31","author":"van Munster","year":"2017","journal-title":"CNS Drugs"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"103753","DOI":"10.1016\/j.msard.2022.103753","article-title":"The validity, responsiveness, and score interpretation of the PROMISnq physical function - multiple sclerosis 15a short form in multiple sclerosis","volume":"62","author":"Kamudoni","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"106320","DOI":"10.1016\/j.msard.2025.106320","article-title":"Which type of PROMs to use in MS routine clinical care: the validity of PROMIS CAT questionnaires","volume":"95","author":"Beckerman","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.msard.2019.05.019","article-title":"Review: patient-reported outcomes in multiple sclerosis care","volume":"33","author":"D'Amico","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/1352458519892555","article-title":"Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment","volume":"26","author":"Cohen","year":"2020","journal-title":"Mult Scler"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1177\/1352458520946005","article-title":"Wearable technologies to measure clinical outcomes in multiple sclerosis: a scoping review","volume":"27","author":"Alexander","year":"2020","journal-title":"Mult Scler J"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e44428","DOI":"10.2196\/44428","article-title":"Wearable sensor technologies to assess motor functions in people with multiple sclerosis: systematic scoping review and perspective","volume":"25","author":"Woelfle","year":"2023","journal-title":"J Med Internet Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"107204","DOI":"10.1016\/j.cmpb.2022.107204","article-title":"The utility of wearable devices in assessing ambulatory impairments of people with multiple sclerosis in free-living conditions","volume":"227","author":"Sun","year":"202","journal-title":"Comput Methods Prog Biomed"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12984-020-00798-9","article-title":"Inertial sensor-based gait parameters reflect patient-reported fatigue in multiple sclerosis","volume":"17","author":"Ibrahim","year":"2020","journal-title":"J Neuroeng Rehabil"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"878313","DOI":"10.3389\/fneur.2022.878313","article-title":"The role of remote monitoring in evaluating fatigue in multiple sclerosis: a review","volume":"13","author":"Block","year":"2022","journal-title":"Front Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s00415-016-8334-6","article-title":"Continuous daily assessment of multiple sclerosis disability using remote step count monitoring","volume":"264","author":"Block","year":"2017","journal-title":"J Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1006932","DOI":"10.3389\/fdgth.2023.1006932","article-title":"Feasibility and scalability of a fitness tracker study: results from a longitudinal analysis of persons with multiple sclerosis","volume":"5","author":"Sieber","year":"2023","journal-title":"Front Digit Health"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41746-024-01025-8","article-title":"Modeling multiple sclerosis using mobile and wearable sensor data","volume":"7","author":"Gashi","year":"2024","journal-title":"NPJ Digit Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1109\/JBHI.2020.2998187","article-title":"Smartphone- and smartwatch-based remote characterisation of ambulation in multiple sclerosis during the two-minute walk test","volume":"25","author":"Creagh","year":"2021","journal-title":"IEEE J Biomed Health Inform"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e37683","DOI":"10.2196\/37683","article-title":"Digital devices for assessing motor functions in mobility-impaired and healthy populations: systematic literature review","volume":"24","author":"Guo","year":"2022","journal-title":"J Med Internet Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1422078","DOI":"10.3389\/fneur.2024.1422078","article-title":"Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study","volume":"15","author":"Borriello","year":"2024","journal-title":"Front Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jval.2019.02.004","article-title":"PROMIS\u00ae adult health profiles: efficient short-form measures of seven health domains","volume":"22","author":"Cella","year":"2019","journal-title":"Value Health"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The multiple sclerosis impact scale (MSIS-29): a new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1177\/13524585231205962","article-title":"Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: the CLARIFY-MS study","volume":"29","author":"Brochet","year":"2023","journal-title":"Mult Scler"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/13524585251333228","article-title":"P321 improvements in health-related quality of life and preserved cognitive function in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS extension study. ACTRIMS forum 2025 \u2013 posters","volume":"31","author":"Langdon","year":"2025","journal-title":"Mult Scler J"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"105376","DOI":"10.1016\/j.ijmedinf.2024.105376","article-title":"Use of wearables among multiple sclerosis patients and healthcare professionals: a scoping review","volume":"184","author":"Alsulami","year":"2024","journal-title":"Int J Med Inform"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e35684","DOI":"10.2196\/35684","article-title":"Wearing the future-wearables to empower users to take greater responsibility for their health and care: scoping review","volume":"10","author":"Kang","year":"2022","journal-title":"JMIR Mhealth Uhealth"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1212\/CPJ.0000000000000382","article-title":"Wearable biosensors to monitor disability in multiple sclerosis","volume":"7","author":"Bradshaw","year":"2017","journal-title":"Neurol Clin Pract"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1177\/1352458519857075","article-title":"Beyond center-based testing: understanding and improving functioning with wearable technology in MS","volume":"25","author":"Brichetto","year":"2019","journal-title":"Mult Scler"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/7627643","article-title":"The role of wearable devices in multiple sclerosis","volume":"2018","author":"Sparaco","year":"2018","journal-title":"Mult Scler Int"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e52179","DOI":"10.2196\/52179","article-title":"Attributes, methods, and frameworks used to evaluate wearables and their companion mHealth apps: scoping review","volume":"12","author":"Moorthy","year":"2024","journal-title":"JMIR Mhealth Uhealth"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1765153\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:32:23Z","timestamp":1775831543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1765153\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":47,"alternative-id":["10.3389\/fneur.2026.1765153"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1765153","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1765153"}}